Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population

Vaccine

Volumn 25, Issue 5, 2007, Pages 927-931

  Rendi Wagner, Pamela ^a,b   Korinek, Maria ^a   Winkler, Birgit ^a   Kundi, Michael ^a   Kollaritsch, Herwig ^a,b   Wiedermann, Ursula ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Center for Travel Medicine   (Austria)

Author keywords

Adults; Antibody persistence; Hepatitis A vaccines; Long term protection

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE TITRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HUMAN; IMMUNITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTECTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VACCINATION; VIRUS TITRATION;

ADULT; AGE FACTORS; AGED; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TIME FACTORS; VACCINATION;

EID: 33845188743     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.044     Document Type: Article

References (25)

1. Koff R.S. Hepatitis A. Lancet 351 (1998) 1643-1649
2. World Health Organization. Hepatitis A vaccines. Weekly Epidemiol Rec 75 (2000) 38-44
3. Mutsch M., Spicher V.M., Gut C., and Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 42 (2006) 490-497
4. Jong E.C. Risks of hepatitis A and B in the traveling public. J Travel Med 8 Suppl 1 (2001) S3-S8
5. Van Herck K., Van Damme P., Lievens M., and Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 72 (2004) 194-196
6. Bell B.P. Hepatitis A vaccine. Pediatr Infect Dis J 19 (2000) 1187-1188
7. André F., Van Damme P., Safary A., and Banatvala J.E. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety, and review of official recommendations of use. Expert Rev Vaccines 1 (2002) 9-23
8. Wiedermann G., Kundi M., Ambrosch F., Safary A., D'Hondt E., and Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 15 (1997) 612-615
9. Wiedermann G., Kundi M., and Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop 69 (1998) 121-125
10. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60 (2000) 1-7
11. Bovier P.A., Bock J., Loutan L., Farinelli T., Glueck R., and Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68 (2002) 489-493
12. Van Herck K., Renard D., Molensberghs G., and Van Damme P. Model-based estimates of long-term persistence of vaccine-induced hepatitis A antibodies. In: Margolis H.S., Alter M.J., Liang T.J., and Dienstag J.L. (Eds). Viral hepatitis and liver disease (2002), International Medical Press, London 56-59
13. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19 (2001) 2055-2060
14. Wiedermann G., Ambrosch F., André F.E., Hondt E.D., Delem A., and Safary A. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10 Suppl. 1 (1992) S129-S131
15. Holzmann H., Croy C., Kundi M., and Popow-Kraupp T. Quantitative determination of hepatitis A virus antibodies in vaccinees: is it necessary?. Proceedings of the third annual meeting of the European society for clinical virology (ESCV), September 1-5 (1999) [Abstract 59]
16. Frisch-Niggemeyer W., and Kunz C. The incidence of antibodies to hepatitis A in people from Vienna and certain Austrian provinces. Wien Klin Wochenschr 91 (1979) 230-233
17. Prodinger W.M., Larcher C., Solder B.M., Geissler D., and Dierich M.P. Hepatitis A in Western Austria-the epidemiological situation before the introduction of active immunisation. Infection 22 (1994) 53-55
18. Alper C.A., Kruskall M.S., Marcus-Bagley D., Craven D.E., Katz A.J., and Brink S.J. Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med 321 (1989) 708-712
19. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 87 Suppl 3A (1989) 36-40
20. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., et al. Hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
21. Van Herck K., and Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 63 1 (2001) 1-7
22. Werzberger A., Kuter B., and Nalin D. Six years follow-up after hepatitis A vaccination. N Engl J Med 338 16 (1998) 1160
23. Lemon S.M. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol 18 Suppl. 2 (1993) 15-19
24. Cederna J.B., Klinzman D., and Stapleton J.T. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18 (2000) 892-898
25. Purcell R.H., D'Hondt E., Bradbury R., Emerson S.U., Govindarajan S., and Binn L. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 10 Suppl 1 (1992) 148-151